Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of SL-11047 in treating patients with relapsed or refractory lymphoma.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label, nonrandomized, dose-escalation study.
Patients receive SL-11047 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of SL-11047 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically* confirmed Hodgkin's or non-Hodgkin's lymphoma (NHL) of any histology
The following NHL types are eligible:
Relapsed after or refractory to ≥ 2 prior therapeutic regimens OR patient is ineligible to receive potentially curative therapy
Bidimensionally measurable or evaluable (e.g., bone marrow or infiltrative organ involvement) disease by physical exam or radiographic study
No suspicion or evidence of lymphomatous meningitis
PATIENT CHARACTERISTICS:
Life expectancy ≥ 12 weeks
ECOG performance status 0-4
Not pregnant
Negative pregnancy test
Fertile patients must use medically prescribed contraception
Absolute neutrophil count ≥ 1,000/mm^3*
Platelet count ≥ 50,000/mm^3*
Hemoglobin ≥ 8 g/dL*
Serum creatinine ≤ 2.0 mg/dL
Total bilirubin ≤ 2.0 mg/dL**
Transaminases < 5 times upper limit of normal**
No other malignancy within the past 5 years other than curatively treated non-metastatic skin cancer or in situ cervical carcinoma
No history of significant or symptomatic cardiac arrhythmia
No history of myocardial infarction
No significant ventricular conduction abnormality by ECG or Holter monitoring, as evidenced by any of the following:
No history of pancreatitis
No history of recent gastrointestinal bleeding
NOTE: **Elevated due to direct lymphomatous involvement allowed
PRIOR CONCURRENT THERAPY:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal